Brought to you by:
Give people a fair chance and watch the results
Ten years ago when we wrote a paper on diversity that was published in the Journal of Vascular Surgery (JVS), it barely caused a ripple. Entitled “Diversity in membership and leadership positions in a regional vascular society,” it was co-authored…
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to 30 days
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray, MD, an interventional cardiologist at Main Line Health, Philadelphia, during the second and final late-breaking data…
Anatomy of a branding campaign: Making vascular surgery more visible
Members asked; SVS listened. The Society for Vascular Surgery (SVS) has launched a Branding Toolkit to help its members brand the specialty in order to elevate and differentiate their practices. This first set of branding tools tells referring physicians what…
Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes in drug-coated device cohort
Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device versus non-drug-coated device treatment for reducing limb outcomes. Connie Hess, MD, an associate professor of cardiology…
New committee needs volunteers
The Society for Vascular Surgery (SVS) has extended the deadline for volunteers to apply to its new Communications Committee. The Society is seeking members who are currently not on an SVS committee and have a desire to shape and align…
Utilize new SVS Branding Toolkit
The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and at no cost to members of the Society for Vascular Surgery (SVS). Additionally, most are customizable…
‘Alea iacta est’: The case for endovascular methods in vascular trauma care
When Benjamin W. Starnes, MD, talks vascular trauma, he does so from a position of certain authority. As the recent Southern California Vascular Surgical Society (SCVSS) annual meeting (Oct. 24–25) heard, few in modern practice can draw on the sort…
Janssen applies to FDA for new indication to expand use of rivaroxaban in PAD patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a new indication to expand the use of Xarelto (rivaroxaban) in patients with…
‘Fundamental differences’ in outcomes after open AAA detected across three national registries
An investigation of differences in patient outcomes following open repair of abdominal aortic aneurysms (AAAs) found in three national registries showed that mortality rates were lower for those contained in the Vascular Quality Initiative (VQI). Researchers at Brigham and Women’s…
New analysis finds DCBs lead to greater four-year survival after fempop revascularization
Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation than those who received treatment using an uncoated device, researchers behind a propensity-matched retrospective review at…